Since hypercholesterolemia patients have a trained immunity phenotype, as we reported (8, 73, 74), which accelerates vascular inflammation and atherosclerosis (44, 45); and hypercholesterolemia stimulates angiotensin peptide synthesis (75), our finding provides a novel insight that targeting Ang II levels by using ACEIs may inhibit trained immunity in patients with hypercholesterolemia, atherosclerosis, heart failure, myocardial infarction, and aortic aneurysms. Here, AGT is linked to myocardial infarction.